Prognostic Significance of the Density and Spatial Distribution of Tumor-Associated Macrophages in Giant Cell Tumor of Bone and Their Association With Denosumab Treatment Responsiveness. [PDF]
MedComm (2020)From January 2015 to December 2020, 393 samples of GCTB were collected from five centers. The density of CD68+ TAMs, CD163+ TAMs, and IRF8+ TAMs was counted by computer‐aided image analysis, and their spatial parameters including NND and EP were measured by HALO.
Yang YF +11 more
europepmc +2 more sources
Effects of RANKL-Targeted Therapy in Immunity and Cancer. [PDF]
, 2014 The role of the receptor activator of nuclear factor-κB ligand (RANKL)/RANK system is well characterized within bone, where RANKL/RANK signaling mediates osteoclastogenesis and bone resorption.
Cheng, Michael L, Fong, Lawrence
core +2 more sources
Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation
Current Osteoporosis Reports, 2022 Purpose of Review Inhibition of receptor activator of nuclear factor kappa-B ligand (RANKL) with denosumab is an effective treatment in a number of conditions including osteoporosis where suppression of bone resorption is desired.
Albert S. Kim, C. Girgis, M. McDonald
semanticscholar +1 more source
Positioning novel biologicals in CKD-mineral and bone disorders [PDF]
, 2017 Renal osteodystrophy (ROD), the histologic bone lesions of chronic kidney disease (CKD), is now included in a wider syndrome with laboratory abnormalities of mineral metabolism and extra-skeletal calcifications or CKD-mineral and bone disorders (CKD-MBD),
Covic, Adrian +5 more
core +1 more source
Journal of Bone and Mineral Research, 2021 Osteonecrosis of the jaw (ONJ) is a rare but serious adverse event associated with antiresorptive treatment. There is little evidence regarding the incidence of ONJ among patients with osteoporosis who are treated with denosumab versus bisphosphonates ...
Everts-Graber Judith +9 more
semanticscholar +1 more source
Severe Hypocalcemia With Denosumab Among Older Female Dialysis-Dependent Patients.
Journal of the American Medical Association (JAMA)Importance Dialysis-dependent patients experience high rates of morbidity from fractures, yet little evidence is available on optimal treatment strategies.
Steven T Bird +16 more
semanticscholar +1 more source
Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis [PDF]
Endocrinology and Metabolism, 2015 Denosumab, a fully human recombinant monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL), blocks binding of RANKL to the RANK receptor, found on the surface of osteoclasts and osteoclast precursors, resulting in decreased ...
Yong-Ki Min
doaj +1 more source
Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial [PDF]
, 2015 OBJECTIVES: To evaluate efficacy and safety of three different regimens of denosumab, a fully human monoclonal antibody to receptor activator of nuclear factor kappa B (RANK) ligand (RANKL), for Japanese patients with rheumatoid arthritis (RA). METHODS:
Genant, Harry K. +8 more
core +1 more source
Denosumab and the Risk of Diabetes in Patients Treated for Osteoporosis
JAMA Network OpenKey Points Question Is denosumab associated with a lower risk of developing diabetes? Findings In this cohort study of 68 510 adults, continued treatment of denosumab for osteoporosis was associated with significantly lower risk of developing diabetes ...
Huei‐Kai Huang +6 more
semanticscholar +1 more source
Bone Reports, 2020 Discontinuation of denosumab is associated with the increase of bone turnover markers to above-baseline levels (so-called rebound in bone turnover) and rapid bone loss.
Masafumi Kashii +3 more
doaj +1 more source